Related Experiment Videos

Liver glutathione contents in patients with gastric adenocarcinomas

A Engin1, Z Ferahköse

  • 1Department of Surgery, Faculty of Medicine, Gazi University, Ankara, Turkey.

Tumori
|February 28, 1990
PubMed

Insights

Reduced glutathione (GSH) levels in liver and gastric cancer tissues impact chemotherapy effectiveness and side effects. Monitoring GSH may optimize antineoplastic treatments.

Area of Science:

  • Biochemistry
  • Oncology
  • Pharmacology

Background:

  • Antineoplastic agents often modulate cellular glutathione (GSH) levels by inhibiting GSH-linked enzymes.
  • Intracellular GSH is crucial for the therapeutic efficacy and toxicity of various antineoplastic interventions.

Purpose of the Study:

  • To investigate the role of reduced glutathione (GSH) levels in gastric cancer and liver tissues.
  • To determine the relationship between GSH levels and the efficacy/toxicity of chemotherapy.

Main Methods:

  • Quantification of mean GSH values in gastric cancer tissue, nontumorous glandular mucosa, normal gastric mucosa, and normal liver biopsies.
  • Comparison of GSH levels between different tissue types and patient groups (gastric adenocarcinoma, chemotherapy-treated patients).

Main Results:

  • Mean GSH values were 0.791 mg/g ww in gastric cancer and 0.719 mg/g ww in nontumorous glandular mucosa.
  • Normal gastric mucosa had an average GSH level of 1.709 mg/g, while normal liver biopsies showed a mean of 2.378 mg/g.
  • Hepatocellular GSH concentrations were lower in gastric adenocarcinoma patients and chemotherapy-treated patients compared to normal liver tissue.

Conclusions:

  • Reduced glutathione (GSH) levels in both tumor and liver tissues may influence the efficacy and toxicity of chemotherapeutic agents.
  • These findings suggest that GSH status is a significant factor in cancer treatment outcomes.

Related Concept Videos